Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018)
Planned study · 2019
- Registered population or design
- 130 planned participants with alcohol-associated liver disease. Final enrollment and arm sizes are unavailable.
- Results availability
- The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.
Study data at a glance
- Participants or experimental model
- 130 planned participants with alcohol-associated liver disease. Final enrollment and arm sizes are unavailable.
- Dose, route and schedule
- Multicenter, single-blind, randomized parallel comparison of intramuscular Ventvil dose schedules with placebo. The listing gives 5 mg as vial strength and does not specify the injection frequency or arm schedules.
- Registered study design
- The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.
Protocol source ↗ · Registry entry for VNT-08-2018
Study limitations and source details
Study limitations
- The registry mirror lists the trial as completed in 2020. The registry mirror enumerates 11 organizations. ClinLine gives 12 in its header and lists 11 by name. Both give 130 planned participants. Enrollment, arm doses and schedules, clinical outcomes and adverse-event counts remain unavailable.
- 5 mg is the strength of the injectable vial. The registry record does not establish what each arm received.
Source details
Clinical trial registration
Authorization No. 120, sponsor and contract research organization listings, investigator profiles and accessible Russian conference programs. Public sources provide registration details.
Sources checked
Added to the library
Citation
MedInvest (sponsor). Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018) Russian clinical-trial register entry via ClinLine. Authorization No. 120, 13 March 2019